Celltrion/Pfizer Agree To Wait For Mid-Sept US Inflectra Launch
This article was originally published in PharmAsia News
Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar product Inflectra in the US pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the reference drug.
You may also be interested in...
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.